Analysts expect ProNAi Therapeutics, Inc. (NASDAQ:SRRA) to announce earnings of ($0.20) per share for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for ProNAi Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.18) and the lowest estimate coming in at ($0.21). ProNAi Therapeutics posted earnings of ($0.43) per share during the same quarter last year, which would suggest a positive year over year growth rate of 53.5%. The business is expected to issue its next quarterly earnings results on Friday, August 11th.
On average, analysts expect that ProNAi Therapeutics will report full-year earnings of ($0.84) per share for the current year, with EPS estimates ranging from ($0.90) to ($0.80). For the next fiscal year, analysts expect that the firm will report earnings of ($0.76) per share, with EPS estimates ranging from ($0.80) to ($0.68). Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for ProNAi Therapeutics.
ProNAi Therapeutics (NASDAQ:SRRA) last released its earnings results on Tuesday, May 9th. The biotechnology company reported ($0.26) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by $0.07.
Several equities research analysts have issued reports on the company. Zacks Investment Research upgraded ProNAi Therapeutics from a “hold” rating to a “strong-buy” rating and set a $1.75 price target for the company in a report on Saturday, February 25th. Wedbush restated an “outperform” rating and issued a $4.00 price target on shares of ProNAi Therapeutics in a report on Monday, March 6th. Finally, SunTrust Banks, Inc. upgraded ProNAi Therapeutics from a “hold” rating to a “buy” rating and set a $4.00 price target for the company in a report on Friday, March 10th.
Several hedge funds and other institutional investors have recently bought and sold shares of SRRA. VHCP Management II LLC purchased a new position in ProNAi Therapeutics during the first quarter worth about $200,000. FMR LLC purchased a new position in ProNAi Therapeutics during the first quarter worth about $302,000. Greenleaf Trust purchased a new position in ProNAi Therapeutics during the first quarter worth about $328,000. Nexthera Capital LP purchased a new position in ProNAi Therapeutics during the first quarter worth about $612,000. Finally, PNC Financial Services Group Inc. purchased a new position in ProNAi Therapeutics during the first quarter worth about $1,142,000. Institutional investors and hedge funds own 60.29% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “ProNAi Therapeutics, Inc. (SRRA) Expected to Announce Earnings of -$0.20 Per Share” was first posted by BBNS and is owned by of BBNS. If you are reading this news story on another website, it was illegally copied and reposted in violation of international copyright & trademark laws. The original version of this news story can be read at https://baseballnewssource.com/markets/pronai-therapeutics-inc-srra-expected-to-announce-earnings-of-0-20-per-share-updated-updated/1044216.html.
ProNAi Therapeutics (NASDAQ:SRRA) traded up 1.75% during trading on Friday, reaching $1.16. The company’s stock had a trading volume of 196,621 shares. ProNAi Therapeutics has a 52 week low of $1.10 and a 52 week high of $2.25. The firm’s market cap is $60.63 million. The stock’s 50 day moving average is $1.23 and its 200-day moving average is $1.40.
ProNAi Therapeutics Company Profile
Sierra Oncology, Inc, formerly ProNAi Therapeutics, Inc, is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ProNAi Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProNAi Therapeutics Inc. and related companies with our FREE daily email newsletter.